Optimer Pharmaceuticals Inc

Optimer Pharmaceuticals — Merger or Acquisition (August 2013)

17 slides from Optimer Pharmaceuticals's merger presentation, Aug 1, 2013

  1. Slide 1: Planned Acquisitions of Trius Therapeutics and Optimer Pharmaceuticals

    Planned Acquisitions of Trius Therapeutics and Optimer Pharmaceuticals Accelerating Cubist’s Global Leadership in Acute Care July 30, 2013 Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement 2 This presentation and statements in this conference call regarding the proposed transactions contain forward-looking statements. Any statements contained herein which do not describe historical facts, including but not limited to, statements regarding: the proposed transactio

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures 3 Use of Non-GAAP Financial Measures Cubist uses non-GAAP financial measures, such as non-GAAP adjusted operating income to assess and analyze its operational results and trends and to make financial and operational decisions. Cubist believes these non-GAAP financial meas

  4. Slide 4: Reconciliation of 2017 Non-GAAP Adjusted Operating Income to GAAP

    Non-GAAP Financial Measures Reconciliation of 2017 Non-GAAP Adjusted Operating Income to 2017 GAAP Operating Income Cubist’s Building Blocks of Growth include forward-looking information about the Company's future financial performance, including projected adjusted operating income in 2017 of $700 m

  5. Slide 5: Highly Strategic Acquisitions Would Propel Cubist as Global Leader in Acute Care

    Highly Strategic Acquisitions Would Propel Cubist as Global Leader in Acute Care 5 Strategic Acceleration of Cubist’s Acute Care Leadership Unique, Highly Complementary Assets Financially Sound Transactions; Accretive in 2015

  6. Slide 6: Cubist Building Blocks of Growth (2013–2017)

    Cubist 5 Year Goals (2013 – 2017) 6 A Highly Differentiated Culture $2B in Global Revenue 4 Product Candidates in Late-Stage Clinical Trials $700M in Non-GAAP Adjusted Operating Income Building Blocks of Growth

  7. Slide 7: Highly Strategic Acquisitions Would Propel Cubist as Global Leader in Acute Care

    Highly Strategic Acquisitions Would Propel Cubist as Global Leader in Acute Care 7 Unique, Highly Complementary Assets Highly complementary (individually and together) to Cubist’s current product portfolio Cubist well positioned to maximize value of both: Tedizolid – NDA expected in 2013; Expect HAB

  8. Slide 8: Unique, Complementary Late-Stage Asset: Tedizolid

    8 Unique, Complementary Late-Stage Asset Excellent Fit with Commercial Capabilities U.S. and E.U. rights to tedizolid helps build Cubist’s global acute care leadership Leverages U.S. commercial infrastructure Assuming approval, can help accelerate E.U. profitability/build relationships ahead of poss

  9. Slide 9: DIFICID Performance

    DIFICID Performance 9 Source: ICS Gross orders for CUBICIN®, IMS Gross Sales for other products

  10. Slide 10: Optimer – Marketed Product helping address need in large CDAD Market

    Optimer – Marketed Product helping address need in large CDAD Market 10 Complementary to Commercial Infrastructure Leverage Cubist’s world-class acute care/hospital infrastructure to support growth in US Co-promote agreement extended; expect smooth transition post closing No substantial new investme

  11. Slide 11: Financially Sound Transactions – Accretion Expected in 2015

    Financially Sound Transactions – Accretion Expected in 2015 11 Trius $13.50 per share in cash, or approximately $707M $2.00 non-tradable CVR tied to sales milestones Total transaction value at up to $818M Trius has cash on hand to help fund transaction Assuming approval, would contribute revenue tow

  12. Slide 12: IDSA X Initiative

    IDSA 10 X 20 Initiative IDSA Challenge to industry/ public policy makers: Find a way to deliver at least 10 new antibiotics by the year 2020. Assuming completion of planned acquisitions + success of combined late-stage pipeline: Cubist would ultimately be responsible for 4 of these new antibiotic th

  13. Slide 13: Product and Pipeline Candidates (With Planned Acquisitions)

    Product and Pipeline Candidates – (With Planned Acquisitions) 13 Therapy / Candidate Phase 1 Phase 2 Phase 3 Filing Market Milestones/Highlights CUBICIN® (daptomycin for injection) FY 2012 Net Revenues of $926.4 ENTEREG®(alvimopan) FY 2012 Net Revenues of $40.2M; sNDA filed: PDUFA 10/22/13 DIFICID®(

  14. Slide 14: Strategic Acceleration of Cubist's Global Acute Care Leadership

    Strategic Acceleration of Cubist’s Global Acute Care Leadership Transactions are right in our wheelhouse Co-promote on DIFICID Helped pioneer Gram+ market over past decade Both products fit with importance of delivering value in evolving healthcare environment Should enable acceleration of Internati

  15. Slide 15: Important Additional Information

    Important Additional Information 15 Important Additional Information about the Potential Trius Transaction will be Filed with the U.S. Securities and Exchange Commission This presentation and the statements during this call are not a recommendation, an offer to purchase or a solicitation of an offer

  16. Slide 16: Important Additional Information

    Important Additional Information 16 Important Additional Information about the Proposed Optimer Transaction and Where to Find it. This presentation and the statements during this call shall not constitute an offer of any securities for sale. The acquisition will be submitted to Optimer’s stockholder

  17. Slide 17: Planned Acquisitions of Trius Therapeutics and Optimer Pharmaceuticals

    Planned Acquisitions of Trius Therapeutics and Optimer Pharmaceuticals Accelerating Cubist’s Global Leadership in Acute Care July 30, 2013

Optimer Pharmaceuticals — Merger or Acquisition (August 2013) on 6ix